CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 9 No. 11
 

Applications of QOL Measurements: A Managed Care Perspective

By

Steven R. Peskin, MD, MBA, PacifiCare of Oklahoma, Inc., Tulsa | November 1, 1995

The current application of QOL measurements and outcomes in managed care organizations is minimal, but potential applications are significant, since a fundamental goal of managed care is to optimize member/patient health, well-being, and satisfaction with efficient resource use. The challenge for researchers and clinicians in this field is to demonstrate the validity and value of a select number of instruments and to galvanize practicing physicians to put them to use in their practices. Managed care organizations would then use their influence over providers, including contract requirements and economic incentives, as well as their internal resources for data collection, analysis, and reporting, to push broader application and dissemination of QOL instruments. [ONCOLOGY 9(Suppl):127-128, 1995]



Introduction

The application of quality of life (QOL) measurements, as identified and defined by other articles in this supplement, has little current significance for the vast majority of managed care organizations. Without demonstrated effectiveness of these measurements in real world clinical settings, managed care organizations will not require their application in contracts or provide incentives for their use.

Several well-established staff or group model Health Maintenance Organizations (HMOs) with ties to academic medical centers or involvement in health services research are formally involved in application and evaluation of QOL instruments. The challenge for those academicians and clinicians who believe that use of QOL measurements can lead to improvement in patient well-being and outcomes is to reach a consensus on a set of valid instruments and to convincingly demonstrate the cost effectiveness or cost utility of those instruments.

Challenges Facing Managed Care Organizations

Purchasers of health care benefits, both public and private, are demanding that the aggregate costs increase at a rate no greater than general inflation. In several competitive markets with high levels of managed care penetration, the price paid by some group purchasers (eg, California Employees Public Retirement System) for HMO coverage for employees and/or retirees has actually declined.

Concomitantly, group purchasers of health care, and the individuals who then make a selection from among two or more choices of insurance plans, are evaluating plans based upon a variety of published report cards or rating systems that seek to differentiate plans based on certain aspects of quality of care and service. Examples include the Health Employees Data Information Set [1] (HEDIS 2.5), which provides comparative measures of HMO plans for several primary preventive services, retina examination for diabetics, and rates of low birth weight or very low birth weight infants, and the National Committee for Quality Assurance (NCQA), an HMO accreditation organization [2].

Managed care organizations are being evaluated for their ability both to control health care costs and to provide quality care and service. Thus, plans must devise financial incentives and quality standards for physicians and other providers to achieve both these aims. Insofar as QOL measures in oncology or other disciplines are successful in assisting providers to make better clinical decisions, which take into account patient preferences and lead to greater patient involvement, then managed care organizations will seek out providers or institutions that employ those measures.

Reimbursement Principles

Eddy proposes a set of principles for guiding decision making related to resource allocation for health services [3]. These principles are based on the premise that the financial resources available to provide health services and medical care to populations are limited. If one holds to this premise, as I do, then decisions regarding individual patients cannot be divorced from the broader context of their impact on a particular population being served (eg, a Medicaid program in a particular state or the population covered by one HMO) or on society as a whole.

Accepting this premise also leads to seeking interventions that provide "the greatest good for the greatest number." Approaching resource allocation in this way does not mean that expensive interventions, such as organ transplants, that impact a single individual are rejected. Rather, it amplifies the importance of establishing the benefits, harms, and costs of specific medical interventions.

This process should include patient-focused QOL measurements and rating of outcomes. Armed with this information, as well as other data gathered in clinical trials, clinicians, policy makers, and payers would be better equipped to determine the appropriateness of selected clinical interventions and the subsequent implications for insurance coverage, reimbursement, or investment.

Capitation

The use of capitation as a mechanism for reimbursing providers for health service is growing steadily. Capitation involves making a fixed payment to an individual provider, a medical group, an institution, or an integrated delivery system, for the provision of all medical services covered under that capitation payment. Typically, the capitation payment is made by a managed care organization to a provider on a per member (patient) per month basis. Other types of capitation involve making a fixed payment to an institution for a particular service (eg, a global payment to an institution for hospital, physician, and ancillary service for a bone marrow transplant that might include all pre- and post-transplant care for 1 year).

With the rise of capitation, medical group practices, independent practice associations, and other provider systems are placed in the position of bearing some of the insurance risk for the cost of medical care and health services for defined populations. This risk-bearing necessitates that providers assume accountability for managing care and resources. Physicians in conjunction with other health care providers should be in the best position to make decisions that maximize the health and well-being of the population they serve while maintaining the long-held tradition of advocacy for the individual patient.

For managed care organizations to serve the interests of their members, they must operate with the best available information, to maximize the patient's quality of life and clinical outcome. As QOL research expands and standard instruments become available, the use of QOL measurements and the involvement of patients with shared decision making based on QOL instruments will become increasingly important to the managed care community.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.





1. National Committee for Quality Assurance: HEDIS 2.5, Updated Specifications for HEDIS 2.0. Washington, DC, January 1995.

2. National Committee for Quality Assurance: 1994 Reviewers Guidelines for the Standards for Accreditation. Washington, DC, 1994.

3. Eddy DM: Principles for making difficult decisions in difficult times. JAMA 271:1792-1798, 1994.


 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Skin Lesions
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy